Your browser doesn't support javascript.
loading
NLRP3 concentration, oxidants, and antioxidants in plasma of endometriosis patients undergoing treatment with dienogest.
Ajdary, Marziyeh; Kashi, Abolfazl Mehdizadeh; Derakhshan, Roya; Chaichian, Shahla; Tahermanesh, Kobra; Mehdizadeh, Mehdi; Minaeian, Sara; Govahi, Azam.
Afiliação
  • Ajdary M; Endometriosis Research Center, Iran University of Medical Sciences, Tehran, Iran.
  • Kashi AM; Endometriosis Research Center, Iran University of Medical Sciences, Tehran, Iran.
  • Derakhshan R; Endometriosis Research Center, Iran University of Medical Sciences, Tehran, Iran.
  • Chaichian S; Endometriosis Research Center, Iran University of Medical Sciences, Tehran, Iran.
  • Tahermanesh K; Endometriosis Research Center, Iran University of Medical Sciences, Tehran, Iran.
  • Mehdizadeh M; Reproductive Sciences and Technology Research Center, Department of Anatomy, Iran University of Medical Sciences, Tehran, Iran.
  • Minaeian S; Antimicrobial Resistance Research Center, Institute of Immunology and Infectious Diseases, Iran University of Medical Sciences, Tehran, Iran.
  • Govahi A; Endometriosis Research Center, Iran University of Medical Sciences, Tehran, Iran. Electronic address: azam.govahi@yahoo.com.
J Gynecol Obstet Hum Reprod ; 53(3): 102744, 2024 Mar.
Article em En | MEDLINE | ID: mdl-38346495
ABSTRACT

OBJECTIVE:

NOD-like receptor pyrin domain-containing 3 (NLRP3) is a cytosolic multi-protein complex that induces inflammation and is negatively regulated by progesterone. Previous researches have reported abnormal induction of reactive oxygen species (ROS) and progesterone resistance in endometriosis (EM). Since progesterone regulates ROS level and, consequently, inflammation, our objective is to investigate whether dienogest (DNG) regulates NLRP3 and whether the regulation of NLRP3 inflammasome by DNG in the blood plasma of patients with EM can affect oxidant and antioxidant markers.

METHODS:

Plasma samples were obtained from control and EM patients experiencing pain symptoms to measure the level of NLRP3, oxidants, and antioxidants. Subsequently, these patients were given oral DNG 2 mg/day for six months for drug treatment. After six months, plasma samples were collected from the patients for re-examination.

RESULTS:

The findings indicate that DNG reduced NLRP3 concentration and oxidant production while increasing antioxidant production in blood plasma. By reducing NLRP3, DNG was able to alleviate inflammation and pain caused by inflammation in EM patients.

CONCLUSION:

In conclusion, the use of DNG in EM patients resulted in a decrease in NLRP3 concentration in the patient's plasma. Furthermore, this effect was enhanced by balancing oxidant/antioxidant levels, which may contribute to reducing inflammation associated with EM.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Endometriose / Nandrolona / Antioxidantes Limite: Female / Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Endometriose / Nandrolona / Antioxidantes Limite: Female / Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article